1 Shared/self-/differentiation TAAs (e.g., Melan-A, PSA, CEA) 2 Shared/self-/cancer testis or germinal TAAs (e.g., MAGE, NY-ESO-1) 3 Universal TAAs (e.g., survivin, hIERI) 4 Mutated, unique TAAs The TAAs recognized by…
Fig. 7.1 The figure demonstrates the immune environment of HRS cells in HL, as well as the antibodies located on the cell surface which are considered potential targets for immunotherapy…
Fig. 5.1 Models of pathogenesis of AML. Three possible scenarios for the development of the LSC are shown. Hematopoietic stem cells (HSC) or myeloid progenitors (MP) or both populations are…
Stage Immune phenotype Target Early precursor HLA-DR, TdT, cCD22, CD79a, CD19 CD19 Blinatumomab Intermediate precursor (common) HLA-DR, TdT, cCD22, CD79a, CD19, CD10, CD20 (variable) CD19 Blinatumomab CD20 Rituximab, ofatumumab Late…
